These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 18037415

  • 1. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Malcovati L.
    Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
    [Abstract] [Full Text] [Related]

  • 2. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA.
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [Abstract] [Full Text] [Related]

  • 3. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N.
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [Abstract] [Full Text] [Related]

  • 4. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, Thomas PW, Killick SB.
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E, Kantarjian HM, Koller C, Taher A.
    Cancer; 2008 Mar 01; 112(5):1089-95. PubMed ID: 18186499
    [Abstract] [Full Text] [Related]

  • 8. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C, Clissa C, Stanzani M.
    Recenti Prog Med; 2014 Mar 01; 105(3):123-6. PubMed ID: 24675455
    [Abstract] [Full Text] [Related]

  • 9. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L.
    Clin Lymphoma Myeloma; 2009 Mar 01; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [Abstract] [Full Text] [Related]

  • 10. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.
    Transfusion; 2010 Jan 01; 50(1):190-9. PubMed ID: 19719471
    [Abstract] [Full Text] [Related]

  • 11. Iron overload in MDS-pathophysiology, diagnosis, and complications.
    Gattermann N, Rachmilewitz EA.
    Ann Hematol; 2011 Jan 01; 90(1):1-10. PubMed ID: 20938663
    [Abstract] [Full Text] [Related]

  • 12. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul 01; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 13. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F.
    Blood Rev; 2008 Dec 01; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [Abstract] [Full Text] [Related]

  • 14. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.
    Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, Falda M, Onida F, Bernardi M, Guidi S, Lucarelli B, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Pascutto C, Oneto R, Pirolini L, Fanin R, Bosi A.
    Haematologica; 2010 Mar 01; 95(3):476-84. PubMed ID: 19903678
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P, Rose C.
    Blood Rev; 2009 Dec 01; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O, Hehlmann R, Hastka J.
    Ann Hematol; 2009 Apr 01; 88(4):301-10. PubMed ID: 18758781
    [Abstract] [Full Text] [Related]

  • 20. Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome.
    Cakar MK, Yegin ZA, Baysal NA, Altındal S, Pamukçuoğlu M, Celik B, Yenicesu I.
    Transfus Apher Sci; 2013 Jun 01; 48(3):397-401. PubMed ID: 23619324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.